HIV

DTG/3TC is non-inferior to DTG-based 3-drug ART in children with HIV: D3/Penta 21 week-96 results

2026

Authors: Turkova A, Chan MK, Kekitiinwa AR, Mutuluuza CK, Musoke P, Cressey TR, Violari A, Archary M, Variava E, Rojo P, Welch SB, Thomason MJ, Giaquinto C, Ford D.

Empirical treatment against cytomegalovirus and tuberculosis in severe pneumonia in HIV-infected infants: a randomized controlled clinical trial

2026

Authors: Moraleda C, Rojo P, Dominguez S, Dominguez S, Buck CW, Musiime V, Mujuru HA, Chabala C, Mvalo T, Bramugy J, Madrid L, Sacarlal J, Ghambi L, Fernandez-Luis S,

Sex matters: A Bayesian approach to analyzing sex differences in an African pediatric cohort

2026

Authors: Gastesi Orbegozo I, Ballesteros A, Barnabas S, Barnabas S, Behuhuma O, Lain MG, Nhampossa T, Otwombe K, Rossi P, Giaquinto C, Kuhn L, Reddy K, Cotugno N,

Prime-boost HIVIS DNA and MVA-CMDR regimen induces robust Env and Gag antibody responses in youth living with HIV

2026

Authors: Kim J, Slike B, McCarragher C, Nguyen P, Metzger L, Moreland S, Pinyakorn S, Schluck G, Krebs S, Rao M, Palma P, Robb M; on behalf of the RV534 study group.M,

HIV-1 DNA dynamics with HIVIS DNA/MVA-CDMR vaccinations +/-TLR4 Agonist: the HVRRICANE trial

2026

Authors: Dhummakupt A, Szewczyk J, Barnabas S, Cotton M, Gorelick R, Pinyakorn S, Turk E, DeSouza M, Cotugno N, Maldarelli F, Palma P, Spiegel H, Robb M, Persaud D;

Pharmacokinetics of a Novel Dose Ratio of DTG/FTC/TAF for African Children with HIV (UNIVERSAL1)

2026

Authors: Kamphuis AEM, Mujuru HA, Bwakura-Dangarembizi MF, Kisitu GP, Matovu F, Kaudha E, Mulindwa A, Jacobs TG, Salvadori N, Than-in-at K, Cressey TR, Nardone A, Lallemant M, Burger DM,

SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistance

2026

Authors: Grasa C, Salvadori N, Nardone A, Than-in-at K, Koblansky A, Parry C, Thakkar N, Wang M, Giaquinto C, Rojo P & Cressey RT

Published in: BMC Infectious Diseases

Dosing of ritonavir-boosted darunavir for treatment of HIV in pregnancy

2026

Authors: Sconza R, Taylor GP, Ene L, Kahlert C, van der Wekken-Pas L, Renaud F, Thorne C, Townsend CL.

Published in: AIDS

Intentions and attitudes of caregivers towards enrolment of their children and adolescents living with HIV into remission trials involving analytic treatment interruption

2026

Authors: Peay HL, Otwombe K, Barnabas S, Barrios-Tascon A, Lain MG, Nhampossa T, Rutebarika D, Jupimai T, Archary M, Maiga A-I, Violari A, Spyer MJ, Reddy K, Palma P,

Integrating life course perspectives into research involving people living with perinatally acquired HIV

2026

Authors: Toledo G, Le Prevost M, Judd A, Collins IJ.

Published in: BMC Global and Public Health

Perinatal HIV exposure is associated with long-term alterations in immune marker levels in children

2026

Authors: Avendaño-Ortiz J, Ventosa-Cubillo J, Rodríguez-Jiménez C, Morales-Pérez D, Muñoz-Hernández R, Pavía-Ruz N, Navarro ML, Holguín Á.

Published in: Journal of Infection and Public Health

Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial

2026

Authors: Turkova A, White E, Violari A, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kaudha E, Na-Rajsima S, Ahimbisibwe GM, Variavae E, Archary M, Akhalwaya Y, Puthanakit T,

Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

2026

Authors: Anena D, Chappell E, Nazzinda R, Kiilu C, Chitsamatanga M, Arumugam T, Green A, Mutuluuza CK, Bwakura-Dangarembizi M, Siika A, Archary M, Jafta L, Namukwaya S,

Late diagnosis of paediatric HIV infection in high-income countries: Lessons from the HIV Perinatal Virtual Clinic

2025

Authors: Curto C, Tritzali M, Bamford A, Bailey AC, Lyall EGH, Mackie NE, Tickner N, Foster C; on behalf of the PVC.

Published in: HIV Medicine

Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025

2025

Authors: Ambrosioni J, Levi LI, Alagaratnam J, Sempere A, Mastrangelo A, Paioni P, Mussini C, Marzolini C, Nielsen SD, Béguelin C, Welch S, Koval A, Mendao L,

Changes in body mass index in children and adolescents living with HIV in Europe and Thailand starting dolutegravir 

2025

Authors: Edgar K, The Epidemiology of Pregnancy and Paediatric Infections International Cohort Collaboration (EPPICC) study group

Published in: Open Forum Infectious Diseases

Effectiveness and safety of tenofovir alafenamide fumarate–based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe

2025

Authors: Chappell E, The European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) Study Group

Published in: International Journal of Antimicrobial Agents

Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial

2025

Authors: Bevers LAH, Toledo G, Kisekka M, Kaudha E, Ahimbisibwe GM, Deprez I, Arumugan T, Variava E, Violari A, White I, Bbuye D, Nanduudu A, Mulwanyi E, Amuge P,

Adolescents in phase 3 HIV clinical trials

2025

Authors: Foster C, Ruel T, Ford D, Turner RM, Archary M, Rojo P, Gibb D; Penta-IMPAACT.

Published in: The Lancet Child & Adolescent Health

Research gaps for children who are HIV-exposed but uninfected: outcomes of a research prioritisation workshop

2025

Authors: Wedderburn CJ, Evans C, Abrams EJ, Bamford A, Bekker A, Bunders MJ, Epalza C, Foster C, Frigati L, Goetghebuer T, John-Stewart G, Kahlert CR, Moraleda C, Musiime V,

Weight gain on tenofovir alafenamide fumarate‐based therapy compared to tenofovir disoproxil fumarate‐ and abacavir‐based therapy in children and young people living with HIV in Europe

2025

Authors: The European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) Study Group

Published in: HIV Medicine

Mortality rates and associated factors among people living with perinatally acquired HIV in Europe and Thailand

2025

Authors: O’Rourke J, Chappell E, Collins IJ, Crichton S, Ene L, Le Coeur S, Le Prevost M, Marques L, Naver L, Noguera-Julian A, Pluta M, Prime K,

Growth trajectories before and after switching to dolutegravir in children living with HIV in the ODYSSEY trial

2025

Authors: Chan MK, Crichton S, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kityo CM, Ahimbisibwe GM, Variava E, Violari A, Cotton M, Archary M, Cressey TR, Puthanakit T,

Pregnancies among adolescents and young women on dolutegravir vs standard-of-care in the ODYSSEY trial and effects of the dolutegravir neural tube defect safety alert

2025

Authors: Ahimbisibwe G, Wyncoll J, Mngqibisa R, White E, Bwakura-Dangarembizi M, Kekitiinwa AR, Lugemwa A, Kityo CM, Variava E, Liberty A, Kataike H, Ngampiyaskul C, Cotton MF,

Growth outcomes in children living with HIV in Europe and Thailand before and after starting dolutegravir

2025

Authors: Edgar K, Scott K, Castro H, O’Rourke J, Ene L, Galli L, Goetghebuer T, Henegar C, Hoffmann TU, Koenigs C, Marczyńska M, Naver L, Noguera-Julian A,

Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial

2025

Authors: Wyncoll J, Archary M, Kamolrattana R, Mujuru HA, Kekitiinwa AR, Violari A, Na-Rajsima S, Lugemwa A, Variava E, Cotton M, Kityo CM, Puthanakit T, Königs C,

Causes of death among sub-Saharan African infants living with HIV and hospitalised with severe pneumonia, using minimally invasive autopsies in the EMPIRICAL trial

2025

Authors: Moraleda C, Madrid L, Rakislova N, Buck WC, Sacarlal J, Chabala C, Hurtado JC, Cassia U, Domínguez-Rodríguez S, Carrilho C, Varo R, Torres-Fernandez D, Ballesteros A,

Viral Suppression, Viral Failure, and Safety Outcomes in Children and Adolescents With Human Immunodeficiency Virus (HIV) on Dolutegravir in Europe and Thailand

2025

Authors: Scott K, O’Rourke J, Jackson C, Ene L, Galli L, Goetghebuer T, Henegar C, Königs C, Marczyńska M, Naver L, Noguera-Julian A, Paioni P, Ramos JT,

Are children and adolescents living with HIV in Europe and South Africa at higher risk of SARS-CoV-2 and poor COVID-19 outcomes?

2025

Authors: European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) SARS-CoV-2 Antibody Study Group

Published in: Epidemiology and Infections

Outcomes After Prenatal Exposure to Raltegravir-Containing Antiretroviral Therapy: A Multicohort European Study

2025

Authors: Sconza R, Fernandes G, Bailey H, Peters H, Prieto Tato LM, Illán Ramos M, Aebi-Popp K, Kahlert C, Gamell AM, Frick A, Ene L, Samarina A,

Effect of Empirical Treatment with Valganciclovir on Mortality in Infants with Severe HIV -associated Pneumonia: a multicenter, open-label, randomized factorial clinical trial

2025

Authors: C. Moraleda, A. Tagarro, S. Domínguez-Rodríguez, W.C. Buck, V. Musiime, H. Mujuru, C. Chabala, P.-Y. Iroh-Tam, T. Mvalo, J. Bramugy, L. Madrid, J. Sacarlal, A. Passanduca,

Effectiveness and safety of dolutegravir (DTG) in infants and children aged under 12-years at start of DTG in Europe and Thailand

2025

Authors: Scott K, Castro H, O’Rourke J, Edgar K, Ene L, Galli L, Goetghebuer T, Henegar C, Hoffmann UT, Königs C, Marczyńska M, Naver L, Noguera-Julian A,

Empirical treatment against tuberculosis in infants with HIV-associated pneumonia: a multicenter, open label, randomized factorial clinical trial.

2025

Authors: Tagarro A, Moraleda1 C, Dominguez-Rodríguez S, Buck C, Musiime V, Mujuru H,  Chabala C, Iroh Tam YP, Mvalo T, Bramugy J, Madrid L, Sacarlal J, Passanduca A,

Pharmacokinetic modeling to support WHO-weight band dosing of the new pediatric Darunavir/ritonavir (120/20 mg) fixed-dose combination tablet for children

2025

Authors: Abdalla S, Lallemant M, Compagnucci A, Nardone A, Giaquinto C, Gibb D, Chabala C, Burger D, Hirt D, Cressey RT for the UNIVERSAl-2 Team

Presented at: IAS 2025

Challenges of recruiting children living with HIV failing antiretroviral therapy into a trial for participants with multi-class drug resistance into a prospective clinical trial

2025

Authors: Grasa C, Archary M, Frigati L, Violari A, Patel F, Strehlau R, Camacho-Gonzalex A, Maboa R, Rakhmanina N, Salvadori N, Nardone A, Than-In-At K,Koblansky A, Thakka N,

Characteristics of antiretroviral resistance in participants from the SHIELD trial: a pharmacokinetic and safety study evaluating fostemsavir in children and adolescents living with multi-drug resistant HIV

2025

Authors: Archary M, Frigati L, Violari A, Patel F, Strehlau R, Camacho-Gonzalez A, Maboa R , Rakhmanina N, Grasa C, Salvadori N, Nardone A, Than-In-At K, Parry C, Keegan M,

Efficacy of second-line dolutegravir- versus boosted protease inhibitor-based ART in children and adolescents living with HIV at 96 and 144 weeks: pooled analysis of the ODYSSEY and CHAPAS-4 trials

2025

Presented by: Amuge P on behalf of the CHAPAS-4 trial, ODYSSEY trial and UNIVERSAL teams

Presented at: International Workshop on HIV and Pediatrics

Factors associated with HIV-1 DNA dynamics in early treated childrenwith perinatal HIV

2025

Presented by: Tagarro A, Reddy K, Molechan C, Dominguez-Rodriguez S, Smith T, Spyer M, Barnabas S, Lain M, Otwombe K, Nhampossa T, Maiga A, Rojo P, Giaquinto C,

Switching off dolutegravir in pregnancy during the safety signal period: a multi-cohort European study

2025

Authors: Fernandes G, Chappell E, Sconza R, Bailey H, Dalla Valle G, Aebi-Popp K, Ene L, Floridia M, Gamell A, Illán Ramos M, Peters H, Samarina A, Bamford A,

Switching off dolutegravir in pregnancy during the safety signal period: a multi-cohort European study

2025

Authors: Fernandes G, Chappell E, Sconza R, Bailey H, Valle DG, Aebi-Popp K, Ene L, Floridia M, Gamell A, Ramos IM ,

Brain MRI and neurocognitive characteristics of children and adolescents living with HIV

2025

Authors: Martín-Bejarano García M, Jackson C, Okhonskaia L, Voronin E, Rozenberg V, Titova MA, Kovalenko T, Wedderburn C, Collins IJ, Crichton S, Velo Higueras C, Salvador E,

EVOLUTION OF THE RESERVOIR IN EARLY TREATED CHILDREN WITH HIV-1 IN SUB-SAHARAN AFRICA

2025

Authors: Tagarro A, Reddy K, Barnabas S, Dominguez-Rodriguez S, Lain MG, Rojo P, Palma P, Ndung’u T, Spyer M, Nhampossa T, Otwombe K, Maiga A, Giaquinto C,

1 out of 20 children with HIV can achieve undetectable HIV-1 reservoir in Africa

2025

Authors: Tagarro A, Reddy K, Dominguez S, Barnabas S, Rojo P, Lain MG, Palma P, Cotugno N, Nastuoli E, Giaquinto C, N’Dungu T, Rossi P, on behalf of the EPIICAL Consortium

Presented at: ESPID 2025

View presentation slides

Statistical analysis plan for the “empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia” clinical trial

2025

Authors: Domínguez-Rodríguez S, Lora D, Tagarro A, Moraleda C, Ballesteros Á, Madrid L, Manukyan L, Marcy O, Leroy V, Nardone A, Burger D, Bassat Q, Bates M, Moh R,

Assessment of the steady-state drug-drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescents

2025

Authors: Abdalla S, Compagnucci A, Bamford A, Chan MK, Ramos JT, Riault Y, Saidi Y, Constant V, Nguyen T, Giaquinto C, Tréluyer JM, Cressey TR, Hirt D, the SMILE Study Group,

Viral suppression, viral failure and safety outcomes in children and adolescents living with HIV on dolutegravir in Europe and Thailand 

2025

Authors: Scott K, O’Rourke J, Jackson C, Ene L, Galli L, Goetghebuer T, Henegar C, Königs C, Marczyńska M, Naver L, Noguera-Julian A, Paioni P, Ramos JT,

Penta Network: State-of-the-Art Research in Pediatric Human Immunodeficiency Virus

2025

Authors: Rojo P, Moraleda C, Giaquinto C

Published in: Clinics in Perinatology

Infants with HIV starting ART withing 4 months of age can achieve sustained undetectable HIV-1 DNA

2025

Authors: Tagarro A, Reddy K, Dominguez-Rodriguez S, Rojo P, Barnabas S, Otwombe K, Lain MG, Maiga A, Kuhn L, Palma P, Cotugno N, Nastuoli E, Giaquinto C,

Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

2025

Authors: White E, Kityo C, Spyer MJ, Mujuru HA, Nankya I, Kekitiinwa AR, Lugemwa A, Kaudha E, Liberty A, Cassim H, Archary M, Cotton MF, Ahimbisibwe GM, Cressey TR,

Long-term non-progression in children living with HIV: estimates from international cohort data.

2025

Authors: Jackson C, Crichton S, Judd A, Bamford A, Goulder P, Klein N, Marques L, Paioni P, Riordan A, Spoulou V, Vieira VA, Ansone S, Chiappini E,

12345678